Press releases

Eevia Health Oyj First Quarter Interim Report 2021

Seinäjoki, Finland, May 18th, 2021 - Eevia releases an adjusted Interim Report for Q1-21 and makes plans to list its shares in Sweden. After a shareholders' decision on April 21st, Eevia Health Oy has changed its legal form from a private limited company to a public limited company and became Eevia Health Oyj. In the same decision the share capital was increased to EUR 80.000, which followed a pre-IPO equity issue of EUR 1,2 million completed in January 2021.

Eevia Health Oyj is a Finnish producer of organic-certified plant extracts. The company is experiencing rapid growth and to finance needed capacity expansion, the company is preparing an Initial Public Offering (IPO). The IPO will be followed by listing for public trading of its shares at an MTF-exchange in Stockholm.

"For Eevia Health Oyj to be able to compete properly in a EUR 500 billion international nutraceuticals market, we need access to capital to meet the strong demand with more capacity" states CEO, Stein Ulve from Eevia Health Oyj.

Click here to download the report.

Kim Nurmi-Aro, CFO
Eevia Health Oyj
Mobile: +358 50 444 0717
Email: kim@eeviahealth.com

ABOUT EEVIA HEALTH OYJ

Eevia Health Oyj, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant material from the pristine Finnish forests near the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. The focus is on ingredients that protect human health prophylactically, meaning they work to reduce the risk of deteriorating health or even developing a disease. In its portfolio, Eevia Health has immune-modulating products that have effects on Th1-type cytokines, such as IFN- and TNF-α cell signaling molecules, which are very important in the immune response to pathogens (virus, bacteria). Similarly, Eevia Health is developing a new product that prevents protein accumulation in the RPE-cells in the Retina, which may reduce the risk of developing eye disease AMD (Age-Related Macular Degeneration).

Eevia Health is a small, but fast-growing Finnish manufacturer of 100% organically certified plant extracts. Most of its raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion. The safe and effective ingredients of high quality, such as high concentrate bilberry anthocyanin extracts (36%) and pine bark extracts (70% oligomeric proanthocyanidins), are organically certified. Eevia Health operates a modern green-chemistry production facility in Finland, located close to the raw materials. The short value-chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.

2021-08-13
Regulatory

The Board and CEO of Eevia Health Plc hereby present the Interim Report for the second quarter 2021, covering the period April 1st through June 30th, 2021. The complete report with tables is attached to this release as a pdf-file. It is also available on the company website at www.eeviahealth.com 

2021-08-05

Eevia Health Plc, ("Eevia" or "The Company"), has installed new capacities and automation equipment for processing and evaporation of natural plant extract liquids. As of August 1st, the newly installed machines and technologies are working satisfactorily, with improved yield, productivity, and cost efficiency. These investments support the company's strong growth and strategic positioning, as communicated in the May 2021 information memorandum.

2021-07-01

Eevia Health Plc, ("Eevia" or "The Company"), announces that it has received sales orders from Ingredient Plus of Australia for supply of bilberry extract with minimum 36% anthocyanins. The sales value of these orders is c. SEK 3 million, which to be prepaid and delivered in Q3-21.

2021-06-29

Eevia Health Plc recently succeeded with an IPO equity round, issuing new 3 451 000 shares with gross proceeds of approx. SEK 26,2 million, leading to a total of 13 951 500 shares in the company as per today's date. Trading in shares will take place from today, June 29, 2021 at Spotlight Stock Market. The short name for the share is EEVIA.

2021-06-22
Regulatory

The Annual General Meeting of shareholders of Eevia Health Plc was held in Seinäjoki, on June 22, 2021. Two shareholders representing 3 797 500 shares and votes (36,14% of total shares) were represented at the meeting. The AGM decided each and all the proposals from the Board of Directors as described in the Notice of Annual General Meeting, unanimously.

2021-06-17

This is a correction to earlier press release today, which stated that the equity issue was over-subscribed by over 400%. The correct is subscribed by over 400%. Also in one media channel the MAR label was omitted by mistake in the Press release itself.

Eevia Health Plc ("Eevia"), a fast-growing functional foods company, today announces that the new share issue of approximately SEK 26.2 million prior to the planned listing on Spotlight Stock Market, was heavily oversubscribed. Subscriptions from over 3,500 investor accounts for a total subscription value of SEK 109.0 million means that the share issue was subscribed 4.16 times (or 416%). 

2021-06-17
Regulatory

Eevia Health Plc ("Eevia"), a fast-growing functional foods company, today announces that the new share issue of approximately SEK 26.2 million prior to the planned listing on Spotlight Stock Market, was heavily oversubscribed. Subscriptions from over 3,500 investor accounts for a total subscription value of SEK 109.0 million means that the share issue was subscribed 4.16 times (or 416%).

1
2